The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations
BS Finkelman, H Zhang, DG Hicks, BM Turner - Cancers, 2023 - mdpi.com
Simple Summary Cellular proliferation is a central determinant of breast cancer recurrence
risk and response to chemotherapy. The discovery of the Ki-67 antibody by Dr. Johannes …
risk and response to chemotherapy. The discovery of the Ki-67 antibody by Dr. Johannes …
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update
KH Allison, MEH Hammond, M Dowsett… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) …
Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) …
Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update
KH Allison, MEH Hammond… - … of pathology & …, 2020 - meridian.allenpress.com
Purpose.—To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen receptor (ER) and progesterone …
Oncology/College of American Pathologists estrogen receptor (ER) and progesterone …
Incorporating biology into breast cancer staging: American Joint Committee on Cancer, revisions and beyond
EA Mittendorf, JMS Bartlett, DL Lichtensztajn… - American Society of …, 2018 - ascopubs.org
Higher-quality imaging, refined surgical procedures, enhanced pathologic evaluation, and
improved understanding of the impact of tumor biology on treatment and prognosis have …
improved understanding of the impact of tumor biology on treatment and prognosis have …
mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants
M Eckstein, RM Wirtz, M Gross-Weege… - International journal of …, 2018 - mdpi.com
Recently, muscle-invasive bladder cancer (MIBC) has been subclassified by gene
expression profiling, with a substantial impact on therapy response and patient outcome. We …
expression profiling, with a substantial impact on therapy response and patient outcome. We …
Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
L Chen, Y Chen, Z Xie, J Luo, Y Wang, J Zhou… - Breast Cancer Research …, 2022 - Springer
Purpose Currently, the most commonly applied method for the determination of breast
cancer subtypes is to test estrogen receptor (ER), progesterone receptor (PR), human …
cancer subtypes is to test estrogen receptor (ER), progesterone receptor (PR), human …
Ki‐67 Expression by Immunohistochemistry and Quantitative Real‐Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy …
P Prihantono, M Hatta, C Binekada… - Journal of …, 2017 - Wiley Online Library
Background. Chemotherapy has become a standard of treatment in managing breast
cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki …
cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki …
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®
Z Varga, A Lebeau, H Bu, A Hartmann… - Breast Cancer …, 2017 - Springer
Background Accurate determination of the predictive markers human epidermal growth
factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor …
factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor …
[HTML][HTML] A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on …
M Eckstein, RM Wirtz, C Pfannstil, S Wach, R Stoehr… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Background Immunohistochemical PD-L1 assessment is currently used to identify
responders towards checkpoint inhibitors although it is limited by inter-observer effects …
responders towards checkpoint inhibitors although it is limited by inter-observer effects …
Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR …
TH Ecke, PC Voß, T Schlomm, A Rabien… - International Journal of …, 2022 - mdpi.com
Patients with muscle-invasive urothelial carcinoma achieving pathological complete
response (pCR) upon neoadjuvant chemotherapy (NAC) have improved prognosis …
response (pCR) upon neoadjuvant chemotherapy (NAC) have improved prognosis …